Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Can portal hypertension and hepatic decompensation be predicted?

Kaji K, Yoshiji H.

J Gastroenterol. 2020 Jan 21. doi: 10.1007/s00535-020-01669-9. [Epub ahead of print] No abstract available.

PMID:
31965301
2.

Levodopa-responsive retrocollis on the background of choreic dyskinesia.

Kataoka H, Sawada Y, Shimozato N, Inatomi S, Yoshiji H, Sugie K.

Int J Neurosci. 2019 Dec 17:1-3. doi: 10.1080/00207454.2019.1692836. [Epub ahead of print]

PMID:
31714814
3.

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.

Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H.

World J Gastrointest Oncol. 2019 Oct 15;11(10):887-897. doi: 10.4251/wjgo.v11.i10.887.

4.

Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.

Tsuji Y, Kawaratani H, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Takaya H, Shimozato N, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H.

Dig Dis. 2019 Oct 25:1-6. doi: 10.1159/000504044. [Epub ahead of print]

PMID:
31655803
5.

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.

Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H.

BMC Gastroenterol. 2019 Oct 21;19(1):167. doi: 10.1186/s12876-019-1082-1.

6.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.

Cells. 2019 Sep 26;8(10). pii: E1153. doi: 10.3390/cells8101153.

7.

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.

Nakanishi K, Namisaki T, Mashitani T, Kaji K, Ozaki K, Saikawa S, Sato S, Inoue T, Sawada Y, Kitagawa K, Takaya H, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.

Nutrients. 2019 Sep 7;11(9). pii: E2140. doi: 10.3390/nu11092140.

8.

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.

Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Dec;25(4):381-389. doi: 10.3350/cmh.2019.0037. Epub 2019 Aug 13.

9.

Effect of furosemide on muscle cramps in patients with liver cirrhosis.

Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

J Gastroenterol Hepatol. 2020 Jan;35(1):76-81. doi: 10.1111/jgh.14820. Epub 2019 Aug 16.

PMID:
31385352
10.

A pancreatic mucinous cystic neoplasm undergoing intriguing morphological changes over time and associated with recurrent pancreatitis: A case report.

Shioyama E, Mitoro A, Ogawa H, Kubo T, Ozutsumi T, Kitagawa K, Yoshikawa M, Ueda S, Akahori T, Marugami NA, Hatakeyama K, Yamao J, Sho M, Ohbayashi C, Yoshiji H.

Medicine (Baltimore). 2019 Jul;98(28):e16435. doi: 10.1097/MD.0000000000016435.

11.

Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study.

Hiraoka A, Yoshiji H, Iwasa M, Nakanishi H, Karino Y, Nakajima T, Miyaaki H, Shiraki M, Kawaguchi T, Sawada Y, Michitaka K, Okita K.

Eur J Gastroenterol Hepatol. 2019 Dec;31(12):1557-1562. doi: 10.1097/MEG.0000000000001473.

PMID:
31180989
12.

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.

Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15.

PMID:
31177586
13.

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.

Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H.

Int J Mol Sci. 2019 Jun 3;20(11). pii: E2724. doi: 10.3390/ijms20112724.

14.

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.

Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H.

World J Gastrointest Oncol. 2019 May 15;11(5):424-435. doi: 10.4251/wjgo.v11.i5.424.

15.

Diagnostic Efficacy of Liquid-Based Cytology in Endoscopic Ultrasound-Guided Fine Needle Aspiration for Pancreatic Mass Lesions During the Learning Curve: A Retrospective Study.

Mitoro A, Nishikawa T, Yoshida M, Sawai M, Okura Y, Kitagawa K, Seki K, Furukawa M, Ozutsumi T, Takeuchi M, Morita K, Ohbayashi C, Yamao J, Yoshiji H.

Pancreas. 2019 May/Jun;48(5):686-689. doi: 10.1097/MPA.0000000000001304.

PMID:
31091216
16.

Identification of clinical risk factors for histological progression of primary biliary cholangitis.

Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14.

PMID:
31021038
17.

Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model.

Kitade M, Kaji K, Nishimura N, Seki K, Nakanishi K, Tsuji Y, Sato S, Saikawa S, Takaya H, Kawaratani H, Namisaki T, Moriya K, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1034-1045. doi: 10.1111/hepr.13351. Epub 2019 May 29.

PMID:
30989766
18.

Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report.

Kaneko M, Namisaki T, Takaya H, Mori H, Kitade M, Okura Y, Seki K, Sato S, Nakanishi K, Kitagawa K, Ozutsumi T, Shimozato N, Kaji K, Otani T, Nakai T, Obayashi C, Mitoro A, Yamao J, Yoshiji H.

J Med Case Rep. 2019 Mar 7;13(1):64. doi: 10.1186/s13256-019-1977-z.

19.

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Mar;25(1):65-73. doi: 10.3350/cmh.2018.0070. Epub 2019 Feb 25.

20.

Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.

Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, Namisaki T, Hashimoto N, Kawata K, Takahashi A, Ninomiya M, Kang JH, Arakawa M, Yamagiwa S, Joshita S, Umemura T, Sato K, Kaneko A, Kikuchi K, Itakura J, Nomura T, Kakisaka K, Fujii H, Kawada N, Takikawa Y, Masaki T, Ohira H, Mochida S, Yoshiji H, Iimuro S, Matsuzaki Y, Takikawa H; Japan PBC Study Group.

Hepatology. 2019 Dec;70(6):2035-2046. doi: 10.1002/hep.30552. Epub 2019 Apr 12.

PMID:
30737815
21.

Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials.

Kawaguchi T, Suzuki F, Imamura M, Murashima N, Yanase M, Mine T, Fujisawa M, Sato I, Yoshiji H, Okita K, Suzuki K.

Hepatol Res. 2019 Apr;49(4):404-418. doi: 10.1111/hepr.13300. Epub 2019 Feb 1.

22.

[Ruptured ascending colonic varices in a patient with alcoholic liver cirrhosis treated using topical skin adhesive:a case study].

Masuda H, Kawaratani H, Takeda S, Sato S, Takaya H, Okura Y, Uejima M, Yamao J, Matsumura M, Yoshiji H.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(12):1087-1093. doi: 10.11405/nisshoshi.115.1087. Japanese.

PMID:
30531115
23.

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.

Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.

J Gastroenterol. 2019 Apr;54(4):367-376. doi: 10.1007/s00535-018-1532-5. Epub 2018 Nov 29.

24.

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.

Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H.

BMC Cancer. 2018 Nov 26;18(1):1164. doi: 10.1186/s12885-018-5099-6.

25.

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.

United European Gastroenterol J. 2018 Nov;6(9):1401-1409. doi: 10.1177/2050640618779660. Epub 2018 May 25.

26.

Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.

Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Mar;49(3):284-295. doi: 10.1111/hepr.13281. Epub 2018 Dec 12.

PMID:
30365236
27.

A Histologically Proven Case of Autoimmune Hepatitis with Eosinophilic Fasciitis.

Asada S, Douhara A, Murata K, Yanase K, Tsutsumi M, Yoshiji H.

Intern Med. 2019 Mar 1;58(5):667-673. doi: 10.2169/internalmedicine.1299-18. Epub 2018 Oct 17.

28.

A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.

Nakamura K, Sho M, Akahori T, Nagai M, Nishiwada S, Nakagawa K, Tanaka T, Kichikawa K, Tamamoto T, Hasegawa M, Mitoro A, Yoshiji H, Ikeda N.

World J Surg. 2019 Feb;43(2):642-648. doi: 10.1007/s00268-018-4820-6.

PMID:
30298284
29.

Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.

Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H; Japan AIH Study Group.

PLoS One. 2018 Oct 4;13(10):e0204772. doi: 10.1371/journal.pone.0204772. eCollection 2018.

30.

Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.

Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H.

Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19.

31.

Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.

Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Feb;49(2):232-238. doi: 10.1111/hepr.13249. Epub 2018 Oct 9.

PMID:
30198141
32.

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

J Gastrointest Oncol. 2018 Aug;9(4):741-749. doi: 10.21037/jgo.2018.05.13.

33.

Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis.

Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, Kikuchi K, Yasunaka T, Takaki A, Ueno Y, Honda A, Matsuzaki Y, Takikawa H.

Sci Rep. 2018 Aug 22;8(1):12542. doi: 10.1038/s41598-018-31063-8.

34.

Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.

Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Mitoro A, Yoshiji H.

Cancer Lett. 2018 Oct 10;434:120-129. doi: 10.1016/j.canlet.2018.07.021. Epub 2018 Jul 19.

PMID:
30031758
35.

Management of refractory cirrhotic ascites: challenges and solutions.

Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H.

Hepat Med. 2018 Jul 3;10:55-71. doi: 10.2147/HMER.S136578. eCollection 2018. Review.

36.

Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug.

Yoshiji H, Karino Y, Suzuki Y, Suzuki F, Uejima M, Aikata H, Chayama K, Iwai H, Suzuki E, Kumada H.

Hepatol Res. 2018 Dec;48(13):1178-1183. doi: 10.1111/hepr.13228. Epub 2018 Aug 9.

PMID:
30005445
37.

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model.

Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H.

Oncotarget. 2018 Jun 19;9(47):28638-28651. doi: 10.18632/oncotarget.25587. eCollection 2018 Jun 19.

38.

[Short-term sustained virological response in a patient with liver cirrhosis, hepatitis C, and declining hepatic spare ability during treatment with direct-acting antivirals].

Mori H, Takaya H, Namisaki T, Noguchi R, Hanatani J, Kaneko M, Seki K, Okura Y, Kitade M, Mitoro A, Yamao J, Yoshiji H.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(5):476-484. doi: 10.11405/nisshoshi.115.476. Japanese.

PMID:
29743456
39.

Gut Dysbiosis Associated With Hepatitis C Virus Infection.

Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y.

Clin Infect Dis. 2018 Aug 31;67(6):869-877. doi: 10.1093/cid/ciy205.

PMID:
29718124
40.

Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG).

J Gastroenterol. 2018 Oct;53(10):1151-1158. doi: 10.1007/s00535-018-1465-z. Epub 2018 Apr 16.

PMID:
29663077
41.

Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: A nationwide study.

Iwasa M, Karino Y, Kawaguchi T, Nakanishi H, Miyaaki H, Shiraki M, Nakajima T, Sawada Y, Yoshiji H, Okita K, Koike K.

Liver Int. 2018 Dec;38(12):2309-2316. doi: 10.1111/liv.13745. Epub 2018 May 30.

PMID:
29582541
42.

Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection : A case report and literature review.

Takaya H, Kawaratani H, Kaneko M, Takeda S, Sawada Y, Kitade M, Moriya K, Namisaki T, Sawai M, Mitoro A, Yamao J, Yoshiji H.

Acta Gastroenterol Belg. 2017 Apr-Jun;80(2):317-319.

PMID:
29560700
43.

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.

J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2.

PMID:
29500489
44.

Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis.

Tanaka A, Hirohara J, Nakano T, Yagi M, Namisaki T, Yoshiji H, Nakanuma Y, Takikawa H; Japan PBC Study Group (JPBCSG).

Hepatol Res. 2018 Aug;48(9):727-734. doi: 10.1111/hepr.13068. Epub 2018 Mar 7.

PMID:
29405510
45.

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H.

Hepatol Commun. 2017 Sep 19;1(9):928-945. doi: 10.1002/hep4.1104. eCollection 2017 Nov.

46.

Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report.

Kaneko M, Mitoro A, Yoshida M, Sawai M, Okura Y, Furukawa M, Namisaki T, Moriya K, Akahane T, Kawaratani H, Kitade M, Kaji K, Takaya H, Sawada Y, Seki K, Sato S, Fujii T, Yamao J, Obayashi C, Yoshiji H.

BMC Gastroenterol. 2018 Jan 19;18(1):16. doi: 10.1186/s12876-018-0743-9.

47.

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.

Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

World J Gastroenterol. 2017 Dec 21;23(47):8355-8366. doi: 10.3748/wjg.v23.i47.8355.

48.

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus.

Asada S, Kawaratani H, Mashitani T, Kaya D, Nishigori M, Kubo T, Sawada Y, Fujinaga Y, Kaji K, Kitade M, Namisaki T, Moriya K, Mitoro A, Yoshiji H.

Intern Med. 2018 Apr 15;57(8):1087-1092. doi: 10.2169/internalmedicine.9490-17. Epub 2017 Dec 27.

49.

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.

Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H.

Int J Cancer. 2018 Apr 15;142(8):1712-1722. doi: 10.1002/ijc.31193. Epub 2017 Dec 12.

50.

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson's Disease.

Kataoka H, Sawada Y, Namizaki T, Shimozato N, Yoshiji H, Ueno S.

Front Neurol. 2017 Oct 16;8:547. doi: 10.3389/fneur.2017.00547. eCollection 2017.

Supplemental Content

Loading ...
Support Center